MX2022009987A - Método seguro y efectivo para tratar la colitis ulcerosa con el anticuerpo anti-il-12/il23. - Google Patents
Método seguro y efectivo para tratar la colitis ulcerosa con el anticuerpo anti-il-12/il23.Info
- Publication number
- MX2022009987A MX2022009987A MX2022009987A MX2022009987A MX2022009987A MX 2022009987 A MX2022009987 A MX 2022009987A MX 2022009987 A MX2022009987 A MX 2022009987A MX 2022009987 A MX2022009987 A MX 2022009987A MX 2022009987 A MX2022009987 A MX 2022009987A
- Authority
- MX
- Mexico
- Prior art keywords
- ulcerative colitis
- antibody
- safe
- effective method
- treating ulcerative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976582P | 2020-02-14 | 2020-02-14 | |
| PCT/IB2021/051215 WO2021161270A2 (en) | 2020-02-14 | 2021-02-12 | Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009987A true MX2022009987A (es) | 2022-11-10 |
Family
ID=77271772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009987A MX2022009987A (es) | 2020-02-14 | 2021-02-12 | Método seguro y efectivo para tratar la colitis ulcerosa con el anticuerpo anti-il-12/il23. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210253690A1 (https=) |
| EP (1) | EP4103606A4 (https=) |
| JP (1) | JP2023514567A (https=) |
| KR (1) | KR20220141847A (https=) |
| CN (1) | CN115427444A (https=) |
| AU (1) | AU2021218265A1 (https=) |
| BR (1) | BR112022015996A2 (https=) |
| CA (1) | CA3170677A1 (https=) |
| IL (1) | IL295545A (https=) |
| MX (1) | MX2022009987A (https=) |
| WO (1) | WO2021161270A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3263646A1 (en) * | 2022-07-29 | 2024-07-18 | Curium Us Llc | [177lu] lutetium-psma l&t composition, kit, method of making, and method of using thereof |
| WO2025029946A1 (en) | 2023-07-31 | 2025-02-06 | Curium Us Llc | [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009114040A2 (en) * | 2007-09-28 | 2009-09-17 | Centocor Ortho Biotech Inc. | Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses |
| KR20170015920A (ko) * | 2014-06-12 | 2017-02-10 | 에프. 호프만-라 로슈 아게 | FcRn 상호작용이 변화된 항체를 선별하는 방법 |
| CN108290058B (zh) * | 2015-09-17 | 2023-05-16 | 美国安进公司 | 使用il23途径生物标志物预测il23拮抗剂的临床应答 |
| TW201922780A (zh) * | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
| TWI744617B (zh) * | 2018-03-30 | 2021-11-01 | 美商美國禮來大藥廠 | 治療潰瘍性結腸炎之方法 |
-
2021
- 2021-02-12 BR BR112022015996A patent/BR112022015996A2/pt not_active Application Discontinuation
- 2021-02-12 US US17/175,129 patent/US20210253690A1/en not_active Abandoned
- 2021-02-12 IL IL295545A patent/IL295545A/en unknown
- 2021-02-12 EP EP21753729.9A patent/EP4103606A4/en active Pending
- 2021-02-12 CA CA3170677A patent/CA3170677A1/en active Pending
- 2021-02-12 AU AU2021218265A patent/AU2021218265A1/en active Pending
- 2021-02-12 WO PCT/IB2021/051215 patent/WO2021161270A2/en not_active Ceased
- 2021-02-12 CN CN202180028613.4A patent/CN115427444A/zh active Pending
- 2021-02-12 MX MX2022009987A patent/MX2022009987A/es unknown
- 2021-02-12 KR KR1020227031763A patent/KR20220141847A/ko active Pending
- 2021-02-12 JP JP2022548895A patent/JP2023514567A/ja active Pending
-
2023
- 2023-06-16 US US18/210,885 patent/US20240002494A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220141847A (ko) | 2022-10-20 |
| WO2021161270A9 (en) | 2022-03-24 |
| US20210253690A1 (en) | 2021-08-19 |
| EP4103606A4 (en) | 2024-04-10 |
| US20240002494A1 (en) | 2024-01-04 |
| CA3170677A1 (en) | 2021-08-19 |
| BR112022015996A2 (pt) | 2022-10-11 |
| IL295545A (en) | 2022-10-01 |
| WO2021161270A2 (en) | 2021-08-19 |
| WO2021161270A3 (en) | 2021-09-16 |
| CN115427444A (zh) | 2022-12-02 |
| AU2021218265A1 (en) | 2022-10-06 |
| EP4103606A2 (en) | 2022-12-21 |
| JP2023514567A (ja) | 2023-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021003411A (es) | Metodo seguro y eficaz para tratar la colitis ulcerosa con el anticuerpo anti-il12/il23. | |
| EP4487908A3 (en) | Methods of treating crohn's disease and ulcerative colitis | |
| EP4233861A3 (en) | Compositions for treatment of essential tremor | |
| MX2022009987A (es) | Método seguro y efectivo para tratar la colitis ulcerosa con el anticuerpo anti-il-12/il23. | |
| EP1692516A4 (en) | THERAPY PROCESS | |
| PH12020551176A1 (en) | Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent | |
| MX2023011035A (es) | Composición de terapia génica y tratamiento de la miocardiopatía arritmogénica del ventriculo derecho. | |
| WO2013062959A3 (en) | Continuous subcutaneous administration of interferon-alpha to hepatitis b infected patients | |
| PH12021553055A1 (en) | Methods and compositions for improving outcomes of cancer patients | |
| MX2023004017A (es) | Método para tratar la enfermedad de crohn con anticuerpo anti-il12/il23. | |
| MX2022013923A (es) | Metodos para tratar la enfermedad de crohn con el anticuerpo especifico anti-il23. | |
| EP4424381A3 (en) | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody | |
| ZA202211308B (en) | Endoxifen for the treatment of bipolar i disorder | |
| PH12022553441A1 (en) | Compositions and methods for treating obsessive-compulsive disorder | |
| MX2024005197A (es) | Métodos para tratar la enfermedad de crohn con el anticuerpo específico anti-il23. | |
| MX2023008876A (es) | Tratamiento de la apnea del sueño con cannabidiol (cbd). | |
| Zhang et al. | Intraoperative tumor lysis-induced fatal hyperkalemia | |
| EA032959B9 (ru) | Применение бремеланотида в терапии женской сексуальной дисфункции | |
| Wood | New local therapy strategies for brain tumours | |
| MX2024008256A (es) | Metodos de tratamiento de la enfermedad por coronavirus y compuestos para el mismo. | |
| MX2024005860A (es) | Métodos para tratar la enfermedad de crohn con el anticuerpo específico anti-il23. | |
| EA202190858A1 (ru) | Безопасный и эффективный способ лечения язвенного колита с помощью антител к il-12/il-23 | |
| Gu et al. | " Tongdu Yisui" acupuncture and moxibustion for 15 cases of Meige syndrome | |
| Fuerst | Yoga benefits lung cancer patients & their caregivers | |
| LI et al. | Clinical observation of acupoint embedding on constipation after stroke |